rHIgM22

DRUG2 trials

Sponsors

Acorda Therapeutics

Conditions

Multiple SclerosisMultiple Sclerosis, Acute Relapsing

Phase 1

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis

CompletedNCT01803867

Acorda TherapeuticsMultiple Sclerosis

Start: 2013-03-31End: 2015-01-31Updated: 2015-02-27

An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse

CompletedNCT02398461

Acorda TherapeuticsMultiple Sclerosis, Acute Relapsing

Start: 2015-04-30End: 2017-09-21Updated: 2018-08-22

Related Papers

A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapse

Multiple Sclerosis Journal - Experimental Translational and Clinical2022-04-0110 citations

Novel approaches for the development of peripheral nerve regenerative therapies

Neural Regeneration Research2015-01-013 citations